|
|
Vaccine Detail
|
Antigen-targeted Personalized Breast Cancer Vaccine |
| Vaccine Information |
- Vaccine Name: Antigen-targeted Personalized Breast Cancer Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007270
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- gp100 (PMEL)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: (Zhang et al., 2017)
- Description: An individualized, therapeutic cancer vaccine (IVAC) composed of liposomes containing RNA encoding two or three tumor associated antigens (TAAs) that are specifically expressed in the patient's individual cancer selected from a warehouse (""off the shelf"") and p53 RNA, with potential immunostimulatory and antineoplastic activities. Upon administration, the antigen-targeted personalized breast cancer vaccines are translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL) and memory T-cell immune responses against the TAAs. The RNAs in the vaccine are specifically selected for an individual patient after RNA profiling of the patient's tumor. (NCIT_C120039).
|
| Host Response |
|
|
| References |
NCIT_C120039: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C120039]
Zhang et al., 2017: Zhang X, Sharma PK, Peter Goedegebuure S, Gillanders WE. Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine. 2017; 35(7); 1094-1100. [PubMed: 27449681].
|
|
